Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2023 Feb 7.
Published in final edited form as: Nature. 2022 Sep;609(7927):E8. doi: 10.1038/s41586-022-05226-7

Author Correction: PHGDH heterogeneity potentiates cancer cell dissemination and metastasis

Matteo Rossi 1, Patricia Altea-Manzano 2, Margherita Demicco 3, Ginevra Doglioni 4, Laura Bornes 5, Marina Fukano 6, Anke Vandekeere 7, Alejandro M Cuadros 8, Juan Fernández-García 9, Carla Riera-Domingo 10, Cristina Jauset 11, Mélanie Planque 12, H Furkan Alkan 13, David Nittner 14, Dongmei Zuo 15, Lindsay A Broadfield 16, Sweta Parik 17, Antonino Alejandro Pane 18, Francesca Rizzollo 19, Gianmarco Rinaldi 20, Tao Zhang 21, Shao Thing Teoh 22, Arin B Aurora 23, Panagiotis Karras 24, Ines Vermeire 25, Dorien Broekaert 26, Joke Van Elsen 27, Maximilian M L Knott 28, Martin F Orth 29, Sofie Demeyer 30, Guy Eelen 31, Lacey E Dobrolecki 32, Ayse Bassez 33, Thomas Van Brussel 34, Karl Sotlar 35, Michael T Lewis 36, Harald Bartsch 37, Manfred Wuhrer 38, Peter van Veelen 39, Peter Carmeliet 40, Jan Cools 41, Sean J Morrison 42, Jean-Christophe Marine 43, Diether Lambrechts 44, Massimiliano Mazzone 45, Gregory J Hannon 46, Sophia Y Lunt 47, Thomas G P Grünewald 48, Morag Park 49, Jacco van Rheenen 50, Sarah-Maria Fendt 51
PMCID: PMC9904429  NIHMSID: NIHMS1864580  PMID: 36042336

In the version of this article initially published, we unintentionally omitted to indicate that Extended Data Fig. 2h and Extended Data Fig. 3f display images from the same experiment. The upper panel in Extended Data Fig. 3f represents green and red channels of the same tumour region as the panel on the top left in Extended Data Fig. 2h. The lower panel in Extended Data Fig. 3f represents green and red channels of the same tumour region as the panel on the top right in Extended Data Fig. 2h. This has now been clarified in Extended Data Fig. 2h and Extended Data Fig. 3f legends and in the Methods “Orthotopic mouse models: Melanoma” subsection, as reflected in the HTML and PDF versions of the article.

Extended Data Fig. 2h. Representative pictures of PHGDH protein expression in primary and metastatic melanoma mouse model (Tyr::N-Ras+/Q61K;Ink4a−/−). Left panels represent tumours from mice injected with melanoma cells alone; middle and right panels represent tumors from mice co-injected with melanoma and Bend3 endothelial cells (ratio 1:4). Green, Phgdh; red, dsRed tumour cell marker; blue, DAPI nuclear staining.

Extended Data Fig. 3f. Representative pictures of PHGDH protein expression in primary melanoma model (Tyr::N-Ras+/Q61K;Ink4a−/−) from mice injected with melanoma cells alone or co-injected with melanoma and Bend3 endothelial cells (ratio 1:4). Outcome of this experiment is also depicted in Extended Data Fig 2h. Upper panel represents green and red channels of the same tumor region as the panel on the top left in Extended Data Fig. 2h. Lower panel represents green and red channels of the same tumour region as the panel on the top right in Extended Data Fig. 2h. Green, Phgdh; red, dsRed tumour cell marker; blue, DAPI nuclear staining. Scale bar 200 μm.

Methods “Orthotopic mouse models: Melanoma” subsection.

Primary melanoma tumour from Tyr::N-RasQ61K;Ink4a−/− (Tyr::creERT2) animals was dissociated into small pieces using forceps and scissors. Tissue was digested using a mix of collagenase I (2 mg ml−1, Sigma-Aldrich, C0130) and IV (2 mg ml−1, Sigma-Aldrich, C5138) for 20 min at 37 °C followed by a trypsin (trypsin-EDTA 0.05%, Thermo Fisher Scientific, 25300054) digestion for 5 min at 37 °C. Single cells were separated from the remaining tissue using a 40 μm cell strainer and cultured in vitro using DMEM supplemented with 10% fetal bovine serum and 100 μg ml−1 penicillin–streptomycin.

Tyr::N-Ras+/Q61K;Ink4a−/− mouse melanoma cells stably expressing dsRed-encoding lentiviruses and Bend3 immortalized endothelial cells stably expressing GFP encoding lentiviruses were mixed at a ratio 1:4 (105 melanoma, 4 × 105 endothelial cells) and resuspended in Matrigel (5 mg ml−1; Thermo Fisher Scientific, 356255). Then, melanoma cells alone or mixed with Bend3 cells were injected subcutaneously into the back skin of Foxn1nu mice. Mice were euthanized when tumours and organs were collected, 25 days after melanoma initiation. Tumour volume was monitored using callipers and the volume was calculated using the following formula: V = (π/6) × length × width × height.

Mice were housed in filter-top cages and IVC cages. Housing and experimental animal procedures were approved by the Institutional Animal Care and Research Advisory Committee of KU Leuven, Belgium. The animal study complies with ethical regulations and was approved by the KU Leuven ethics committee. Humane end points were determined as follows: tumour size of 1.8 cm3, loss of ability to ambulate, unhealthy fur; difficult respiration because of lung metastasis, surgical infection or weight loss over 20% of initial body weight. Mice were monitored and, after detection of one of the above-mentioned symptoms, the mouse was euthanized.

Footnotes

Correction to: Nature https://doi.org/10.1038/s41586-022-04758-2 Published online 18 May 2022

Contributor Information

Matteo Rossi, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Patricia Altea-Manzano, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Margherita Demicco, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Ginevra Doglioni, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Laura Bornes, Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Marina Fukano, Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, Quebec, Canada; Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada; Rosalind & Morris Goodman Cancer Institute (GCI), McGill University, Montreal, Quebec, Canada.

Anke Vandekeere, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Alejandro M. Cuadros, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium

Juan Fernández-García, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Carla Riera-Domingo, Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology (CCB), VIB, Leuven, Belgium; Laboratory of Tumor Inflammation and Angiogenesis, Department of Oncology, KU Leuven, Leuven, Belgium.

Cristina Jauset, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.

Mélanie Planque, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

H. Furkan Alkan, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium

David Nittner, Histopathology Expertise Center, VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium; Department of Oncology, KU Leuven, Leuven, Belgium.

Dongmei Zuo, Rosalind & Morris Goodman Cancer Institute (GCI), McGill University, Montreal, Quebec, Canada.

Lindsay A. Broadfield, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium

Sweta Parik, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Antonino Alejandro Pane, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Francesca Rizzollo, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Gianmarco Rinaldi, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Tao Zhang, Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.

Shao Thing Teoh, Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA.

Arin B. Aurora, Children’s Research Institute and Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA

Panagiotis Karras, Department of Oncology, KU Leuven, Leuven, Belgium; Laboratory of Molecular Cancer Biology, VIB Center for Cancer Biology, Leuven, Belgium.

Ines Vermeire, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Dorien Broekaert, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Joke Van Elsen, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

Maximilian M. L. Knott, Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany

Martin F. Orth, Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany

Sofie Demeyer, Laboratory for Molecular Biology of Leukemia, VIB-KU Leuven, Leuven, Belgium.

Guy Eelen, Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU Leuven, Leuven, Belgium; Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology, VIB, Leuven, Belgium.

Lacey E. Dobrolecki, StemMed, Houston, TX, USA

Ayse Bassez, Laboratory for Translational Genetics, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.

Thomas Van Brussel, Laboratory for Translational Genetics, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.

Karl Sotlar, Institute of Pathology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.

Michael T. Lewis, StemMed, Houston, TX, USA

Harald Bartsch, Institute of Pathology, Ludwig Maximilians University, Munich, Germany.

Manfred Wuhrer, Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.

Peter van Veelen, Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.

Peter Carmeliet, Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU Leuven, Leuven, Belgium; Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology, VIB, Leuven, Belgium; Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Laboratory of Angiogenesis and Vascular Heterogeneity, Department of Biomedicine, Aarhus University, Aarhus, Denmark.

Jan Cools, Laboratory for Molecular Biology of Leukemia, VIB-KU Leuven, Leuven, Belgium.

Sean J. Morrison, Children’s Research Institute and Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA; Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA

Jean-Christophe Marine, Department of Oncology, KU Leuven, Leuven, Belgium; Laboratory of Molecular Cancer Biology, VIB Center for Cancer Biology, Leuven, Belgium.

Diether Lambrechts, Laboratory for Translational Genetics, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.

Massimiliano Mazzone, Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology (CCB), VIB, Leuven, Belgium; Laboratory of Tumor Inflammation and Angiogenesis, Department of Oncology, KU Leuven, Leuven, Belgium; Department of Molecular Biotechnology and Health Science, Molecular Biotechnology Centre, University of Torino, Torino, Italy.

Gregory J. Hannon, Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK

Sophia Y. Lunt, Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA; Department of Chemical Engineering and Materials Science, Michigan State University, East Lansing, MI, USA

Thomas G. P. Grünewald, Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany; Hopp Children’s Cancer Center (KiTZ), Heidelberg, Germany; Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany

Morag Park, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada; Rosalind & Morris Goodman Cancer Institute (GCI), McGill University, Montreal, Quebec, Canada.

Jacco van Rheenen, Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Sarah-Maria Fendt, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium; Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Leuven, Belgium.

RESOURCES